Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy
This case series describes the management and outcomes of ocular toxic effects associated with mirvetuximab soravtansine therapy in female patients with folate receptor α–positive gynecologic malignant neoplasms.
Authors
- Saba Al-Hashimi (ORCID: https://orcid.org/0000-0001-9957-4511)
- Jordyn Silverstein (ORCID: https://orcid.org/0000-0002-8573-7145)
- Edmund Yik Kong Tsui (ORCID: https://orcid.org/0000-0001-7532-9191)
- Gottfried E. Konecny (ORCID: https://orcid.org/0000-0001-6083-657X)
- S. Fung (ORCID: https://orcid.org/0000-0001-9905-636X)
- Reza S. Ghaffari
- Ali J. Haidar
- Angela Chen
- Judy L. Chen
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- Doheny Eye Institute (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1001/jamaoncol.2025.5763
- Primary Topic
- Retinoids in leukemia and cellular processes
- Type
- article
- Field-Weighted Citation Impact
- 0.00